Significance of phosphoinositide 3kinase/AKT pathway alterations in endometrial carcinoma

Chinese Journal of Pathology

Volumn 40, Issue 12, 2011, Pages 799-804

  Yang, Xi ^a   Dong, Ying ^a   Zhang, Xiao Ming ^a   Liang, Ying ^a   Zhang, Ying ^a   Meng, Yi Ting ^a   Wang, Ying ^a   Wang, Wei ^a   Nong, Lin ^a   Ting, L I ^a   Liao, Qin Pmg ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

1 phosphatidylinositol 3 kinase; Endometrial neoplasms; Mutation; Prognosis; Protein kinases

Indexed keywords

ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; EXON; FEMALE; FOLLOW UP; GENETICS; HUMAN; HYSTERECTOMY; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84862789584     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2011.12.003     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4):225-249.
2. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control, 2009, 16 (1): 8-13.
3. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res, 2005, 65(23):10669-10673. (Pubitemid 41713332)
4. Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol, 2009, 22(4) : 522-529.
5. Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol, 2008, 21(2): 131-139. (Pubitemid 351172164)
6. Catasus L, D'Angelo E, Pons C, et al. Expression profiling of 22 genes involved in the P13 K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol, 2010, 23(5): 694-702.
7. Konstantinova D, Kaneva R, Dimitrov R, et al. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer. DNA Cell Biol, 2010, 29(2):65-70.
8. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PD kinase activation. Proc Natl Acad Sci U S A, 2009, 106(12):48344839.
9. Fattaneh A, Tavassoli FA, Devilee P. Epithelial tumours and related lesions//Tavassoli FA, Devilee P. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon; IARC Press, 2003: 221-232.
10. Esteva FJ, Guo H, Zhang S, et al. PTEN, P1K3CA, p-AKT, and p-p70S6K status; association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol, 2010, 177(4):1647-1656
11. Bogusiewicz M, Semczuk A, Gogacz M, et al. Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas. Cancer Lett, 2006, 238(1):61-68. (Pubitemid 43851145)
12. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002, 2(7): 489-501. (Pubitemid 37328931)
13. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol, 2009,113(3):370-373.
14. Peiró G, Lohse P, Mayr D, et al. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol, 2003, 120(1) :78-85. (Pubitemid 37046373)
15. Creighton CJ, Fu X, Hennessy BT, el al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER + breast cancer. Breast Cancer Res,2010,12(3) : R40.
16. Tokunaga E, Oki E, Kimura Y, et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat, 2007, 101(3): 249-257. (Pubitemid 46169878)
17. Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol, 2004, 130(3): 161-168. (Pubitemid 38392349)
18. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma; correlation with PTEN and K-RAS alterations. Hum Pathol, 2006, 37(11): 1465-1472. (Pubitemid 44584324)
19. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res, 2006, 12(20 Pt 1) :5932-5935. (Pubitemid 44703751)
20. Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science, 2006, 314(5807): 1930-1933. (Pubitemid 46026115)
21. Zhao D, Li XP, Gao M, et al. Stromal cell-derived factor 1 alpha stimulates human endometrial carcinoma cell growth through the activation of both extracellular signal-regulated kinase 1/2 and Akt. Gynecol Oncol, 2006, 103(3): 932-937. (Pubitemid 44821317)
22. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell, 2009, 16(1): 21-32.